{"id":"stelara","brandName":"Stelara","genericName":"Stelara","companyId":"biocon-biologics-uk-ltd","companyName":"Biocon Biologics UK Ltd","phase":"marketed","status":"approved","modality":"Biologic","aliases":["ustekinumab"],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"","enrichmentLevel":3,"visitCount":4,"mechanism":{"target":"Interleukin-12, Interleukin-23"},"administration":{},"safety":{"commonSideEffects":[{"effect":"Infections","drugRate":"27%","severity":"common","organSystem":""},{"effect":"Infections (long-term follow-up)","drugRate":"72.3%","severity":"common","organSystem":""}],"seriousAdverseEvents":[{"effect":"Malignancies (excluding non-melanoma skin cancer)","drugRate":"1.7%","severity":"serious"},{"effect":"Non-melanoma skin cancer","drugRate":"1.5%","severity":"serious"},{"effect":"Serious infections (long-term follow-up)","drugRate":"2.8%","severity":"serious"},{"effect":"Serious infections (placebo-controlled period)","drugRate":"0.3%","severity":"serious"},{"effect":"Cellulitis","drugRate":"","severity":"serious"},{"effect":"Herpes zoster","drugRate":"","severity":"serious"},{"effect":"Diverticulitis","drugRate":"","severity":"serious"},{"effect":"PRES (Posterior Reversible Encephalopathy Syndrome)","drugRate":"","severity":"serious"}]},"trials":[],"indications":{"approved":[{"name":"Crohn's disease","diseaseId":"crohn's-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Plaque psoriasis","diseaseId":"plaque-psoriasis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Psoriasis","diseaseId":"psoriasis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Psoriasis with arthropathy","diseaseId":"psoriasis-with-arthropathy","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Ulcerative colitis","diseaseId":"ulcerative-colitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[{"nctId":"NCT07495644","phase":"","title":"Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-03-01","conditions":["Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis)"],"enrollment":95,"completionDate":"2027-06"},{"nctId":"NCT07487480","phase":"","title":"A Prospective Observational Study on the Efficacy and Safety of Guselkumab in the Treatment of Crohn's Disease Patients Previously Treated With Ustekinumab","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-02-10","conditions":["Inflamatory Bowel Disease","Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis)"],"enrollment":60,"completionDate":"2028-12-31"},{"nctId":"NCT05092269","phase":"PHASE3","title":"A Long-term Extension Study of Ustekinumab in Pediatric Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-10-18","conditions":["Crohn Disease","Colitis, Ulcerative","Arthritis, Psoriatic"],"enrollment":159,"completionDate":"2028-03-15"},{"nctId":"NCT06045754","phase":"PHASE4","title":"A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-04-18","conditions":["Crohn's Disease"],"enrollment":100,"completionDate":"2027-06-28"},{"nctId":"NCT07234838","phase":"","title":"Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)","status":"RECRUITING","sponsor":"Jonathan Krygier","startDate":"2026-02-01","conditions":["Psoriasis","Condyloma Acuminata","Biotherapies"],"enrollment":600,"completionDate":"2028-08-01"},{"nctId":"NCT07310095","phase":"PHASE4","title":"A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)","status":"RECRUITING","sponsor":"Xian-Janssen Pharmaceutical Ltd.","startDate":"2025-12-30","conditions":["Crohn Disease"],"enrollment":78,"completionDate":"2027-11-15"},{"nctId":"NCT03466411","phase":"PHASE2,PHASE3","title":"A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-13","conditions":["Crohn's Disease"],"enrollment":1409,"completionDate":"2028-01-28"},{"nctId":"NCT07449234","phase":"","title":"A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis","status":"RECRUITING","sponsor":"Janssen-Cilag Ltd.","startDate":"2026-02-09","conditions":["Psoriasis"],"enrollment":200,"completionDate":"2027-09-01"},{"nctId":"NCT05083182","phase":"PHASE3","title":"A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-08-30","conditions":["Arthritis, Juvenile"],"enrollment":50,"completionDate":"2026-12-05"},{"nctId":"NCT03218488","phase":"","title":"A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen-Cilag International NV","startDate":"2017-10-25","conditions":["Psoriasis"],"enrollment":135,"completionDate":"2032-08-31"},{"nctId":"NCT06934226","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-04-15","conditions":["Plaque Psoriasis"],"enrollment":752,"completionDate":"2027-08-20"},{"nctId":"NCT06425549","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis","status":"RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2024-06-25","conditions":["Moderate to Severe Plaque Psoriasis"],"enrollment":168,"completionDate":"2030-11-08"},{"nctId":"NCT04372108","phase":"","title":"A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis","status":"RECRUITING","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2021-06-24","conditions":["Crohn Disease","Colitis, Ulcerative"],"enrollment":1056,"completionDate":"2030-08-30"},{"nctId":"NCT00508547","phase":"","title":"Psoriasis Longitudinal Assessment and Registry","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2007-06-21","conditions":["Psoriasis"],"enrollment":15842,"completionDate":"2030-12-31"},{"nctId":"NCT03646708","phase":"","title":"Response Assessment in SB CD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2018-05-09","conditions":["Small Bowel Crohn's Disease"],"enrollment":112,"completionDate":"2027-05-30"},{"nctId":"NCT07116967","phase":"PHASE3","title":"Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-09-22","conditions":["Plaque Psoriasis"],"enrollment":3040,"completionDate":"2031-01-16"},{"nctId":"NCT06807593","phase":"PHASE2","title":"Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-02-24","conditions":["Cancer"],"enrollment":10,"completionDate":"2027-03-31"},{"nctId":"NCT07444060","phase":"","title":"Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-03-01","conditions":["CD - Crohn's Disease","Stricture; Bowel","IBD - Inflammatory Bowel Disease"],"enrollment":100,"completionDate":"2029-12-31"},{"nctId":"NCT05387031","phase":"","title":"Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-08-01","conditions":["Crohn Disease","Stricture; Bowel","Intestinal Stricture"],"enrollment":239,"completionDate":"2028-08-01"},{"nctId":"NCT06520397","phase":"PHASE4","title":"Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2024-07-15","conditions":["Crohn Disease"],"enrollment":214,"completionDate":"2027-07-31"},{"nctId":"NCT06249555","phase":"","title":"VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study","status":"RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2024-03-20","conditions":["Crohn's Disease"],"enrollment":300,"completionDate":"2026-12"},{"nctId":"NCT07177209","phase":"","title":"Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-02-27","conditions":["Ulcerative Colitis"],"enrollment":4000,"completionDate":"2026-05-31"},{"nctId":"NCT07245394","phase":"","title":"Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)","status":"RECRUITING","sponsor":"TIDHI Innovation Inc.","startDate":"2026-01-29","conditions":["Inflammatory Bowel Disease (IBD)","Crohn Disease (CD)","Ulcerative Colitis (UC)","IBD-unclassified (IBD-U)"],"enrollment":200,"completionDate":"2028-11-01"},{"nctId":"NCT05327790","phase":"PHASE2","title":"LFMT vs Placebo in New Biologic Start for Ulcerative Colitis","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2022-06-03","conditions":["Ulcerative Colitis"],"enrollment":40,"completionDate":"2026-03-31"},{"nctId":"NCT03370133","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2017-12-06","conditions":["Chronic Plaque Psoriasis","Moderate to Severe Chronic Plaque Psoriasis","Psoriatic Arthritis"],"enrollment":567,"completionDate":"2019-12-13"},{"nctId":"NCT04259138","phase":"PHASE4","title":"Determination of the Optimal Treatment Target in Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2020-02-18","conditions":["Colitis, Ulcerative"],"enrollment":672,"completionDate":"2026-03-31"},{"nctId":"NCT07352566","phase":"PHASE4","title":"Utilization of a Microdevice for Psoriasis and Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-01-01","conditions":["Psoriasis","Atopic Dermatitis"],"enrollment":10,"completionDate":"2030-06-01"},{"nctId":"NCT04572815","phase":"PHASE2","title":"Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-05-14","conditions":["Hematologic and Lymphocytic Disorder","Hematopoietic and Lymphoid System Neoplasm"],"enrollment":116,"completionDate":"2027-06-30"},{"nctId":"NCT07303686","phase":"PHASE4","title":"De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2025-10-08","conditions":["Crohn Disease (CD)","Ulcerative Colitis (UC)"],"enrollment":115,"completionDate":"2027-10-15"},{"nctId":"NCT03167437","phase":"PHASE1,PHASE2","title":"An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-10-30","conditions":["Crohn's Disease"],"enrollment":35,"completionDate":"2026-06-30"},{"nctId":"NCT07250815","phase":"","title":"A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease","status":"NOT_YET_RECRUITING","sponsor":"Takeda","startDate":"2025-12-15","conditions":["Ulcerative Colitis","Crohn's Disease"],"enrollment":23900,"completionDate":"2025-12-15"},{"nctId":"NCT04232553","phase":"PHASE3","title":"A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2020-06-22","conditions":["Crohn's Disease"],"enrollment":996,"completionDate":"2027-04"},{"nctId":"NCT07268534","phase":"PHASE2","title":"Biologics in Folliculitis Decalvans : an Adaptative Trial Research","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-04-01","conditions":["Folliculitis Decalvans (FD)"],"enrollment":120,"completionDate":"2030-04-01"},{"nctId":"NCT07263464","phase":"","title":"The Association Between TNFSF4 Polymorphism and CD","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2018-01-01","conditions":["Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)","Polymorphism, Single Nucleotide","Ustekinumab"],"enrollment":818,"completionDate":"2025-05-31"},{"nctId":"NCT04673357","phase":"PHASE3","title":"A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-04-06","conditions":["Crohn Disease"],"enrollment":101,"completionDate":"2025-03-03"},{"nctId":"NCT07244614","phase":"","title":"Ustekinumab in BEhçet's Syndrome STudy","status":"RECRUITING","sponsor":"Groupe français d'étude des Maladies Inflammatoires de loeil","startDate":"2025-09-01","conditions":["Behçet's Syndrome (BS)"],"enrollment":208,"completionDate":"2029-12-31"},{"nctId":"NCT03651518","phase":"PHASE2","title":"Personalized Therapies in Inflammatory Complex Disease","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-10-20","conditions":["Inflammatory Disease","Autoimmune Diseases"],"enrollment":32,"completionDate":"2025-11"},{"nctId":"NCT05535738","phase":"PHASE2,PHASE3","title":"Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation","status":"RECRUITING","sponsor":"Wei-Che Ko","startDate":"2022-11-15","conditions":["Skin Inflammation","Allergic Contact Dermatitis"],"enrollment":45,"completionDate":"2027-12-31"},{"nctId":"NCT04632927","phase":"PHASE3","title":"Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-12-21","conditions":["Psoriatic Arthritis"],"enrollment":119,"completionDate":"2024-10-22"},{"nctId":"NCT06274554","phase":"PHASE3","title":"Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2024-10-04","conditions":["Crohn's Disease","Inflammatory Bowel Diseases"],"enrollment":120,"completionDate":"2029-12"},{"nctId":"NCT07198113","phase":"","title":"COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)","status":"NOT_YET_RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2025-11-01","conditions":["Ulcerative Colitis, Pediatric","Inflammatory Bowel Diseases","Crohn Disease"],"enrollment":1100,"completionDate":"2028-09"},{"nctId":"NCT05029921","phase":"PHASE4","title":"A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-12-10","conditions":["Crohn Disease"],"enrollment":182,"completionDate":"2025-05-18"},{"nctId":"NCT07177118","phase":"PHASE3","title":"Risankizumab for Fibrostenotic Crohn's Disease Treatment","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10-20","conditions":["Crohn Disease","Crohn Disease and Ulcerative Colitis"],"enrollment":260,"completionDate":"2028-10-20"},{"nctId":"NCT05335356","phase":"PHASE3","title":"Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Biocon Biologics UK Ltd","startDate":"2022-06-28","conditions":["Moderate to Severe Chronic Plaque Psoriasis"],"enrollment":384,"completionDate":"2023-11-15"},{"nctId":"NCT02648581","phase":"PHASE2","title":"Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-06-14","conditions":["Behçet Disease"],"enrollment":16,"completionDate":"2019-11-19"},{"nctId":"NCT04978493","phase":"PHASE2","title":"A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2021-12-02","conditions":["Crohn Disease"],"enrollment":49,"completionDate":"2024-08-08"},{"nctId":"NCT07152977","phase":"","title":"Description of the Radiological Response of Anoperineal Fistulizing Lesions of Crohn's Disease","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2019-07-31","conditions":["Anoperineal Lesions","Crohn's Disease Relapse"],"enrollment":52,"completionDate":"2024-07-31"},{"nctId":"NCT07149792","phase":"PHASE4","title":"A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers","status":"RECRUITING","sponsor":"Taichung Veterans General Hospital","startDate":"2025-07-29","conditions":["Psoriasis","Psoriasis Arthritis","Biologics"],"enrollment":50,"completionDate":"2028-06-01"},{"nctId":"NCT07149467","phase":"PHASE3","title":"Ustekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory Crohn's Disease: A Multicenter, Randomized, Parallel-Controlled Study","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2025-09-10","conditions":["Crohn's Disease Aggravated","Crohn's Disease in Remission"],"enrollment":454,"completionDate":"2027-12-31"},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":["Rheumatic Disease"],"enrollment":80,"completionDate":"2027-09"},{"nctId":"NCT03358706","phase":"PHASE1","title":"A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-02","conditions":["Crohn Disease","Ulcerative Colitis"],"enrollment":28,"completionDate":"2021-11-22"},{"nctId":"NCT06738277","phase":"PHASE1","title":"This is Comparative Study in Normal Healthy Subjects to Evaluate Pharmacokinetics, Safety, Tolerability of Bmab 1200 -Autoinjector (AI) After Single Subcutaneous Injection (45 mg) in Comparison With Bmab 1200 -Prefilled Syringe (PFS).","status":"COMPLETED","sponsor":"Biocon Biologics UK Ltd","startDate":"2025-01-09","conditions":["Moderate to Severe Chronic Plaque Psoriasis"],"enrollment":186,"completionDate":"2025-07-12"},{"nctId":"NCT04524611","phase":"PHASE3","title":"Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-09-30","conditions":["Crohn's Disease (CD)"],"enrollment":527,"completionDate":"2028-02"},{"nctId":"NCT07100093","phase":"","title":"Prospective, Multicenter Study on the Association Between Serum Ustekinumab Levels and Clinical, Biological and Endoscopic Remission in Patients With Crohn's Disease.","status":"COMPLETED","sponsor":"Hospital Universitario La Paz","startDate":"2021-07-01","conditions":["Ustekinumab Serum Levels in Patients With Crohn´s Disease"],"enrollment":100,"completionDate":"2022-02-25"},{"nctId":"NCT06788340","phase":"PHASE4","title":"MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease","status":"NOT_YET_RECRUITING","sponsor":"Odense University Hospital","startDate":"2025-09-01","conditions":["Inflammatory Bowel Diseases","Crohn Disease","Ulcerative Colitis"],"enrollment":166,"completionDate":"2027-11-01"},{"nctId":"NCT06488664","phase":"PHASE3","title":"An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AO GENERIUM","startDate":"2023-07-25","conditions":["Plaque Psoriasis"],"enrollment":422,"completionDate":"2025-09-30"},{"nctId":"NCT07077681","phase":"","title":"Evaluation of the Acceptability and Therapeutic Maintenance After Substitution of Ustekinumab With a Biosimilar","status":"RECRUITING","sponsor":"EG Labo","startDate":"2025-06-02","conditions":["Crohn Disease (CD)"],"enrollment":246,"completionDate":"2027-12-31"},{"nctId":"NCT04630028","phase":"PHASE3","title":"A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-03-17","conditions":["Colitis, Ulcerative"],"enrollment":112,"completionDate":"2025-06-05"},{"nctId":"NCT07057856","phase":"","title":"An Analysis of the Relationship Between the Genetic Polymorphisms of Interleukin 12 Receptor Subunit Beta 1 and Crohn's Disease in Chinese Patients","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2018-01-01","conditions":["Crohn's Disease"],"enrollment":866,"completionDate":"2025-05-31"},{"nctId":"NCT07041112","phase":"","title":"Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors","status":"COMPLETED","sponsor":"Juan Ruano Ruiz","startDate":"2012-01-01","conditions":["Psoriasis","Psoriatic Arthritis (PsA)","Cardiovascular Risk Factors","Metabolic Syndrome (MetS)","Drug Survival","Pharmacogenetics"],"enrollment":1000,"completionDate":"2024-06-01"},{"nctId":"NCT06082986","phase":"","title":"A Retrospective Observational Study of Ustekinumab Among Bio-naive Participants With Crohn's Disease in China","status":"COMPLETED","sponsor":"Xian-Janssen Pharmaceutical Ltd.","startDate":"2023-10-09","conditions":["Crohn Disease"],"enrollment":200,"completionDate":"2024-06-05"},{"nctId":"NCT01081730","phase":"","title":"Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database","status":"COMPLETED","sponsor":"Janssen Biotech, Inc.","startDate":"2010-02-09","conditions":["Psoriasis"],"enrollment":2040,"completionDate":"2017-09-29"},{"nctId":"NCT05928039","phase":"PHASE4","title":"PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2023-10-25","conditions":["Crohn Disease"],"enrollment":297,"completionDate":"2028-12-31"},{"nctId":"NCT06997055","phase":"","title":"ROLL'YN-UST: an Observational Study in Patients Treated by Steqeyma®, an Ustekinumab Biosimilar","status":"RECRUITING","sponsor":"Celltrion HealthCare France","startDate":"2025-03-17","conditions":["Crohn Disease","Plaque Psoriasis"],"enrollment":225,"completionDate":"2027-12-31"},{"nctId":"NCT06956703","phase":"","title":"NAZA - Nottingham/Astra ZenecA Prospective IBD Cohort Study","status":"RECRUITING","sponsor":"University of Nottingham","startDate":"2022-12-12","conditions":["Gastro-Intestinal Disorder","Crohn Disease","Ulcerative Colitis","Inflammatory Bowel Diseases"],"enrollment":240,"completionDate":"2027-02-28"},{"nctId":"NCT04967508","phase":"PHASE3","title":"A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2021-07-06","conditions":["Psoriasis","Moderate to Severe Plaque Psoriasis"],"enrollment":503,"completionDate":"2022-11-25"},{"nctId":"NCT04435600","phase":"PHASE3","title":"A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-07-14","conditions":["Psoriasis"],"enrollment":139,"completionDate":"2024-10-15"},{"nctId":"NCT06453317","phase":"PHASE2","title":"Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis","status":"RECRUITING","sponsor":"Medical University of Lodz","startDate":"2025-02-17","conditions":["Ulcerative Colitis","Inflammatory Bowel Diseases"],"enrollment":172,"completionDate":"2028-06-30"},{"nctId":"NCT05242458","phase":"","title":"A Study of Ustekinumab Treatment in Children With Crohn's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-03-21","conditions":["Crohn's Disease"],"enrollment":545,"completionDate":"2023-05-22"},{"nctId":"NCT06954311","phase":"","title":"Therapeutic Drug Monitoring for Biological Therapy in Pediatric Inflammatory Bowel Disease","status":"RECRUITING","sponsor":"Medical University Innsbruck","startDate":"2025-02-17","conditions":["Ulcerative Colitis (UC)","IBD-unclassified (IBD-U)"],"enrollment":120,"completionDate":"2030-02-17"},{"nctId":"NCT03981744","phase":"PHASE3","title":"A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments","status":"TERMINATED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2019-07-26","conditions":["Polymyositis","Dermatomyositis"],"enrollment":51,"completionDate":"2022-07-12"},{"nctId":"NCT03782376","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","startDate":"2018-12-20","conditions":["Crohn Disease"],"enrollment":215,"completionDate":"2023-01-10"},{"nctId":"NCT03517722","phase":"PHASE3","title":"A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-16","conditions":["Lupus Erythematosus, Systemic"],"enrollment":516,"completionDate":"2020-11-05"},{"nctId":"NCT02438787","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-07-31","conditions":["Axial Spondyloarthritis"],"enrollment":315,"completionDate":"2017-08-31"},{"nctId":"NCT02877134","phase":"PHASE2","title":"Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-08-25","conditions":["Crohn Disease"],"enrollment":388,"completionDate":"2022-01-24"},{"nctId":"NCT03464136","phase":"PHASE3","title":"Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2018-03-29","conditions":["Crohn Disease"],"enrollment":386,"completionDate":"2021-05-21"},{"nctId":"NCT02437162","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-09-03","conditions":["Axial Spondyloarthritis"],"enrollment":347,"completionDate":"2017-09-06"},{"nctId":"NCT04882072","phase":"PHASE3","title":"A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)","status":"TERMINATED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2021-09-15","conditions":["Takayasu Arteritis"],"enrollment":14,"completionDate":"2023-05-25"},{"nctId":"NCT02407236","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-07-10","conditions":["Colitis, Ulcerative","Inflammatory Bowel Diseases"],"enrollment":961,"completionDate":"2021-11-30"},{"nctId":"NCT03107793","phase":"PHASE3","title":"Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab","status":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","startDate":"2017-04-19","conditions":["Crohn Disease"],"enrollment":500,"completionDate":"2021-07-20"},{"nctId":"NCT04963725","phase":"","title":"A Study of Symptom Improvement of Ulcerative Colitis After an Induction Dose of Ustekinumab in Japanese Clinical Practice","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2021-07-18","conditions":["Ulcerative Colitis"],"enrollment":137,"completionDate":"2022-12-01"},{"nctId":"NCT03606499","phase":"","title":"Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases","status":"COMPLETED","sponsor":"Janssen Cilag S.A.S.","startDate":"2018-09-26","conditions":["Crohn Disease","Colitis, Ulcerative"],"enrollment":111,"completionDate":"2023-03-17"},{"nctId":"NCT05252533","phase":"PHASE1","title":"A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or Psoriasis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-05-24","conditions":["Juvenile Psoriatic Arthritis","Psoriasis","Arthritis, Juvenile"],"enrollment":31,"completionDate":"2024-01-26"},{"nctId":"NCT00741793","phase":"","title":"Biologic Treatment Registry Across Canada","status":"COMPLETED","sponsor":"Janssen Inc.","startDate":"2002-02-12","conditions":["Arthritis, Rheumatoid","Spondyloarthritis, Axial","Arthritis, Psoriatic"],"enrollment":2821,"completionDate":"2018-06-29"},{"nctId":"NCT03942120","phase":"","title":"Post-Marketing Surveillance for Crohn's Disease Participants Treated With Stelara (Ustekinumab)","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2019-04-08","conditions":["Crohn Disease"],"enrollment":685,"completionDate":"2022-01-14"},{"nctId":"NCT04816513","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of Ustekinumab by Two Different Injection Devices in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-04-14","conditions":["Healthy"],"enrollment":300,"completionDate":"2022-01-26"},{"nctId":"NCT02968108","phase":"PHASE1","title":"A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-01-18","conditions":["Crohn Disease"],"enrollment":45,"completionDate":"2022-03-18"},{"nctId":"NCT04655807","phase":"PHASE2","title":"A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2021-03-03","conditions":["Crohn Disease"],"enrollment":0,"completionDate":"2023-09-04"},{"nctId":"NCT03465696","phase":"NA","title":"A Priming Intervention to Increase Patient Willingness to Use Injectables for the Management of Psoriasis","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2018-05-14","conditions":["Psoriasis"],"enrollment":180,"completionDate":"2019-06-21"},{"nctId":"NCT06935942","phase":"","title":"The Associations of Plasminogen Activator Inhibitor-1 Gene Polymorphisms With Crohn's Disease in Chinese Patients","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2020-01-01","conditions":["Crohn Disease"],"enrollment":906,"completionDate":"2025-01-01"},{"nctId":"NCT06935929","phase":"","title":"A Study on the Associations Between Microribonucleic Acid Gene Polymorphisms and Crohn's Disease","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2020-01-01","conditions":["Crohn Disease"],"enrollment":839,"completionDate":"2025-01-01"},{"nctId":"NCT06912815","phase":"NA","title":"Ustekinumab With Semi-EN vs Exclusive EN for Preoperative Crohn's Disease Optimization.","status":"RECRUITING","sponsor":"Xiang Gao","startDate":"2024-08-01","conditions":["Crohn Disease (CD)"],"enrollment":184,"completionDate":"2026-09"},{"nctId":"NCT03885713","phase":"PHASE4","title":"Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","startDate":"2019-09-10","conditions":["Inflammatory Bowel Diseases","Crohn Disease","Ulcerative Colitis"],"enrollment":180,"completionDate":"2024-12-31"},{"nctId":"NCT04305327","phase":"PHASE3","title":"Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis","status":"TERMINATED","sponsor":"LEO Pharma","startDate":"2022-12-07","conditions":["Psoriasis"],"enrollment":12,"completionDate":"2023-05-05"},{"nctId":"NCT06089590","phase":"","title":"Ibd CAncer and seRious Infections in France (I-CARE 2)","status":"RECRUITING","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","startDate":"2024-01-25","conditions":["IBD","Ulcerative Colitis","Crohn Disease"],"enrollment":6000,"completionDate":"2031-03-01"},{"nctId":"NCT05270733","phase":"PHASE4","title":"Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics","status":"RECRUITING","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2022-11-10","conditions":["Psoriasis"],"enrollment":56,"completionDate":"2026-12-31"},{"nctId":"NCT04533737","phase":"PHASE4","title":"Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab","status":"TERMINATED","sponsor":"LEO Pharma","startDate":"2020-12-17","conditions":["Plaque Psoriasis","Psoriasis Vulgaris","Psoriasis"],"enrollment":113,"completionDate":"2022-12-07"},{"nctId":"NCT05896943","phase":"","title":"The Application of Transcriptomics in the Treatment of Ulcerative Colitis With Ustekinumab","status":"COMPLETED","sponsor":"Evangelismos Hospital","startDate":"2022-04-01","conditions":["Ulcerative Colitis"],"enrollment":38,"completionDate":"2024-09-25"},{"nctId":"NCT04505410","phase":"PHASE3","title":"Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"University of Miami","startDate":"2020-09-18","conditions":["Ulcerative Colitis"],"enrollment":32,"completionDate":"2023-12-07"},{"nctId":"NCT06849739","phase":"","title":"Study on the Correlation and Consistency of Measuring Biologic Drug Plasma Concentrations Based on Different Detection Methods","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-03-02","conditions":["Inflammatory Bowel Diseases"],"enrollment":60,"completionDate":"2025-12-31"}],"genericFilers":[],"biosimilarFilings":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$25519.9560/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$9,187,184","description":"STELARA 45 MG/0.5 ML SYRINGE","retrievedDate":"2026-04-07"}],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"Un","currency":"USD","price_amount":"9187184.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"9187184.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"9187184.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"9187184.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"9187184.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":3,"withResults":2},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Stelara","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:43:18.533026+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:43:24.266940+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stelara","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:43:24.571182+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Interleukin-23 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:43:25.621010+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201835/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:43:25.271845+00:00"}},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:43:27.694244+00:00","fieldsConflicting":1,"overallConfidence":0.8},"crossReferences":{"rxcui":"853351","chemblId":"CHEMBL1201835","pubchemSID":"135302166"},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}